Course info
Description
Provider | American Society of Hematology (ASH) |
Accreditation Type | Physicians—maximum of .50 AMA PRA Category 1 Credit(s)™
Nurses— 0.50 contact hours of nursing continuing professional development credit PAs—maximum of .50 AMA PRA Category 1 Credit(s)™ |
Accreditor | ASH for physicians The France Foundation for nurse and PAs |
Release Date | October 31, 2023 |
Expiration Date | October 31, 2026 |
Estimated Time to Complete Activity | 30 minutes |
Target Audience
Hematologists, hematologists/oncologists, hematology/oncology nurse practitioners, physician associates, and other health care professionals involved in the treatment and management of patients with myelofibrosis.
Program Overview
Myelofibrosis (MF) is a rare and chronic bone marrow disorder characterized by the progressive replacement of normal bone marrow tissue with fibrous scar tissue. This fibrosis scar tissue disrupts the normal production of blood cells in the bone marrow, leading to various complications. This activity will assist clinicians in improving diagnosis for patients with MF. Learners will gain a greater understanding of pathophysiologic mechanisms of MF.
Learning Objectives
Upon completion of this course, the learners should be able to:
- Compare and contrast clinical data on new and emerging agents for MF with a focus on improving QoL
- Identify strategies to prevent, monitor, and manage treatment related adverse effects
- Recognize approaches to ensure shared decision-making and equitable care with patients